Patient Research
Find a studySpecialtiesConditionsTreatmentsBy countryLearn
Sign in
Research.Patient.info

Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 research hub

1 indexed studies · 0 currently recruiting

  • active not recruitingPHASE2

    Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

    This study looks at combining two cancer drugs, tuvusertib and avelumab, for people with advanced Merkel cell skin cancer that hasn't responded to previous treatment. It aims to see if the combination works better than tuvusertib alone to stop the cancer from getting worse.

    United States · Canada
Advertisement
Advertisement
Advertisement
Patient.info Research

Find clinical research studies and trials explained in plain English - powered by Patient.info.

About
  • About us
  • Advertise with us
  • Partnerships
  • Authors
  • Contact us
Research explained
  • What is a clinical trial?
  • Trial phases explained
  • Why volunteer?
  • Clinical research FAQ
  • All health-research articles
Legal
  • About our content
  • Report a correction
  • Accessibility statement
  • Cookie policy
  • Privacy policy
  • Terms of use
  • Editorial policy
Find a study

Search clinical research studies and trials by condition, location and eligibility.

Browse studies →Learn about trials →
Information only. Research.Patient.info surfaces public clinical-trial registry data and explains it in plain English. We are not affiliated with the MHRA, HRA, NHS, NIHR or any regulator. Inclusion of a study is not an endorsement and is not medical advice — always discuss with your own doctor before agreeing to take part. See about our content or report a correction.
© 2026 Navigate Health Ltd. All rights reserved.
Registered number: 16229589
Registered office: 128 City Road, London, United Kingdom, EC1V 2NX.
Patient is a UK registered trade mark.
Patient does not provide medical advice, diagnosis or treatment.